Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ADPT
Adaptive Biotechnologies Corporation
Healthcare | Biotechnology
$17.22-0.24 (-1.37%)as of 2026-07-14 21:20 UTC
Market Cap$2.6B
Volume6.86M
EPS (TTM)$-0.39
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a $2.6B biotechnology company trading at $17.22 (−1.4% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 21:20 UTC.
52-Week Range
Low $9.96High $20.76
What Adaptive Biotechnologies Corporation does
The company develops an immune medicine platform that sequences and analyzes T cell and B cell receptors to diagnose and treat disease. It operates two main businesses: the MRD business, which offers clonoSEQ, an FDA-authorized test for detecting minimal residual disease in lymphoid cancers, and the Immune Medicine business, which uses proprietary datasets to discover disease-related immune signatures and antigens for therapeutic applications.
Summarized from Adaptive Biotechnologies Corporation’s SEC filings · Read the filing ↗
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
What does Adaptive Biotechnologies Corporation do?
The company develops an immune medicine platform that sequences and analyzes T cell and B cell receptors to diagnose and treat disease.
What is ADPT's valuation?
ADPT trades at $17.22, as of 2026-07-14.
When did ADPT last file with the SEC?
Adaptive Biotechnologies Corporation's most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings and public market data feeds, fetched 2026-07-14 21:20 UTC. This page is also available as JSON at /api/data?ticker=ADPT and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ADPT and 3,500+ tickers.
